Search research articles
Contact Us
Filters
Showing results (291-300 of 336) with videos related to
Page
of 34
Sort By:
European Journal of Cancer (Oxford, England : 1990)
|
February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Alessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Frontiers in Oncology
|
February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 study
Veronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Frontiers in Oncology
|
March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study
Francesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Journal of Translational Medicine
|
September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Frontiers in Oncology
|
October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
Sara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.
Clinical Genitourinary Cancer
|
November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study
Brigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
Orazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Cancer Letters
|
June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
Kylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Page
of 34
Search research articles
Search
Showing results (291-300 of 336) with videos related to
Sort By:
Page
of 34
European Journal of Cancer (Oxford, England : 1990)
|
February 29, 2020
Another side of the association between body mass index (BMI) and clinical outcomes of cancer patients receiving programmed cell death protein-1 (PD-1)/ Programmed cell death-ligand 1 (PD-L1) checkpoint inhibitors: A multicentre analysis of immune-related adverse events
Alessio Cortellini, Melissa Bersanelli, Daniele Santini, et al.
Frontiers in Oncology
|
February 27, 2024
Time to strategy failure and treatment beyond progression in pretreated metastatic renal cell carcinoma patients receiving nivolumab: <i>post-hoc</i> analysis of the Meet-URO 15 study
Veronica Murianni, Alessio Signori, Sebastiano Buti, et al.
Cancer Immunology, Immunotherapy : CII
|
May 27, 2025
Pembrolizumab-axitinib versus nivolumab-cabozantinib as first-line therapy in patients with metastatic renal cell carcinoma: a retrospective real-world comparison (ARON-1)
Matteo Santoni, Giandomenico Roviello, Enrique Grande, et al.
Frontiers in Oncology
|
March 6, 2026
Impact of bone-targeting agents on the clinical outcomes in patients with metastatic renal cell carcinoma treated with nivolumab: a sub-analysis of the Meet-URO 15 study
Francesco Pantano, Andrea Malgeri, Ugo De Giorgi, et al.
Journal of Translational Medicine
|
September 30, 2022
The prognostic value of the previous nephrectomy in pretreated metastatic renal cell carcinoma receiving immunotherapy: a sub-analysis of the Meet-URO 15 study
Sara Elena Rebuzzi, Alessio Signori, Giuseppe Luigi Banna, et al.
Frontiers in Oncology
|
October 10, 2022
The prognostic value of baseline and early variations of peripheral blood inflammatory ratios and their cellular components in patients with metastatic renal cell carcinoma treated with nivolumab: The Δ-Meet-URO analysis
Sara Elena Rebuzzi, Alessio Signori, Marco Stellato, et al.
Clinical Genitourinary Cancer
|
November 27, 2024
Prognostic Impact of IMDC Category Shift From Baseline to Nivolumab Initiation in Metastatic Renal Cell Carcinoma: A Sub-Analysis of the MEET-URO 15 Study
Brigida Anna Maiorano, Martina Catalano, Chiara Mercinelli, et al.
European Journal of Cancer (Oxford, England : 1990)
|
August 6, 2021
Docetaxel and prednisone with or without enzalutamide as first-line treatment in patients with metastatic castration-resistant prostate cancer: CHEIRON, a randomised phase II trial
Orazio Caffo, Cinzia Ortega, Franco Nolè, et al.
Cancer Letters
|
June 5, 2024
Safety and efficacy outcomes of early cessation of anti-PD1 therapy in patients 80 years or older: A retrospective cohort study
Kylie Fletcher, Alessio Cortellini, Teja Ganta, et al.
Cancer Immunology, Immunotherapy : CII
|
May 29, 2023
Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
Matteo Santoni, Zin W Myint, Thomas Büttner, et al.
Page
of 34